Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Fosun Invests in Miacom; Will Market and Make its Diagnostic Tests

publication date: Jul 28, 2014
Fosun Pharma acquired a 37% stake in miacom diagnostics GmbH of Germany in early July for an undisclosed sum. Two weeks later, Fosun Diagnostics announced it would market miacom’s molecular beacon-based diagnostic assays in China and Asia. The proprietary multiplex assays are used to detect sepsis- and pneumonia-related pathogens. In addition, Fosun will build an FDA-compliant production facility to manufacture the assays in China for domestic and export markets. More details....

Stock Symbol: (SHA: 600196; HK: 2196)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital